Study of CAD-1883 for Spinocerebellar Ataxia

Summary

This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA). This study offers the opportunity to understand the safety, tolerability, and efficacy of CAD-1883 in the SCA patient population.

Timeline

Start

2021-06

Primary completion

2022-11

Completion

2022-12

Outcome

Outcome not reported

Stopped: “In January 2021 Novartis acquired Cadent Therapeutics. As part of a pipeline reassessment, the Synchrony-1 trial will not proceed as initially scheduled.”

Drugs

Indications